Ann Hematol (2014) 93:1447
DOI 10.1007/s00277-014-2101-5

ERRATUM

Erratum to: High expression of the *Ets-related gene (ERG)* is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia

Anna Hecht · Daniel Nowak · Verena Nowak · Benjamin Hanfstein · Andreas Faldum · Thomas Büchner · Karsten Spiekermann · Cristina Sauerland · Eva Lengfelder · Wolf-Karsten Hofmann · Florian Nolte

Published online: 9 May 2014

Erratum to: Ann Hematol (2013) 92:443–449
DOI 10.1007/s00277-012-1648-2

We have to report that in subsequent studies performed on the same patient cohort investigated for ERG expression in this article, we by chance found that in 7 out of 86 patients the PML/RARA-fusion transcript could not be detected. The reason for this discrepancy with the original diagnostic findings remains unclear. However, repeating our analyses on the remaining cohort of 79 securely PML/RARA-positive APL patients we could confirm our previously reported findings regarding ERG expression levels and prognosis: High expression of ERG (≥75th percentile) in APL patients is associated with an inferior relapse free survival (RFS: 43 % vs 78 % for ERG^{low} after 10 years of follow-up; p=0.004) and an inferior relapse free interval (RFI: 74 % vs. 97 % after 10 years of follow-up; p=0.003). The overall survival of responders to induction therapy was 62 % in the ERG^{high} group compared to 81 % in the ERG^{low} group. However, as reported before, this difference did not yield statistical significance (p=0.11).

The online version of the original article can be found at doi:10.1007/s00277-012-1648-2.

A. Hecht · D. Nowak · V. Nowak · B. Hanfstein · E. Lengfelder · W.-K. Hofmann · F. Nolte (✉)
Department of Hematology and Oncology,
University Hospital Mannheim,
Theodor-Kutzer-Ufer 1-3,
68167 Mannheim, Germany
e-mail: florian.nolte@medma.uni-heidelberg.de

A. Faldum · C. Sauerland
Institute of Biostatistics and Clinical Research,
University of Münster, Münster, Germany

T. Büchner
Department of Hematology/Oncology, University of Münster,
Münster, Germany

K. Spiekermann
Department of Hematology/Oncology, University of Munich,
Munich, Germany